



**VENCOR INTERNATIONAL, INC.  
(PLAD, INC.)**

**ISSUER INFORMATION AND DISCLOSURE STATEMENT  
PREPARED IN ACORDANCE WITH SEC RULE 15c2-11**

**THIS STATEMENT IS COMPILED TO FULFILL THE DISCLOSURE REQUIREMENTS OF OTC PINK (OTC MARKETS, INC.); THE ENUMERATED ITEMS AND CAPTIONS HEREIN CORRESPOND TO THE ITEMS AND CAPTIONS SET FORTH BY THE OTC PINK (OTC MARKETS, INC.)VERSION 9.1 DISCLOSURE GUIDELINES**

**ALL INFORMATION WITHIN THIS DOCUMENT HAS BEEN PREPARED FROM THE BOOKS AND RECORDS OF VENCOR INTERNATIONAL, INC. BY THE OFFICERS AND DIRECTORS OF THE COMPANY.**

**ANY REPRESENTATIONS NOT CONTAINED HEREIN MUST NOT BE RELIED UPON AS HAVING BEEN MADE OR AUTHORIZED BY THE COMPANY.**

As of June 30, 2015

- Item 1** The exact name of the company and its predecessor (if any).  
Vencor International, Inc., a Utah corporation (“VCOR” or the “Company”)  
There have been no predecessor entities or name changes in the past five years.
- Item 2** The address of the company’s principal executive offices.  
5585 Schenck Ave.  
Suite 5  
Rockledge, FL 32955  
  
Website: <http://www.pladinc.com>  
Phone: 844-488-7523  
Email: [info@pladinc.com](mailto:info@pladinc.com)  
  
IR Contact:  
[info@pladinc.com](mailto:info@pladinc.com)
- Item 3** Trading symbol: VCOR  
The Company has the following classes of securities:  
CUSIP: 9252603204  
Common Shares Authorized: 5,000,000,000 (as of 6/30/15)  
Common Shares outstanding: 1,247,053,690 (as of 6/30/15)  
Par Value: \$.00001  
Preferred A Authorized: 5,000,000 (as of 6/30/15)  
Preferred A Outstanding: 4,200,000 (as of 6/30/15)  
Par Value: \$.01  
Preferred B Authorized: 5,000,000 (as of 6/30/15)  
Preferred B Outstanding: 164,000 (as of 6/30/15)  
Par Value: \$.01  
Preferred C Authorized: 100,000,000 (as of 6/30/15)  
Preferred C Outstanding: 10,000,000 (as of 6/30/15)  
Par Value: \$.00001

**The name and address of the transfer agent:**

VStock Transfer, LLC  
18 Lafayette Place  
Woodmere, NY 11598

VStock Transfer, LLC is registered under the Exchange Act.

There are no restrictions on the transfer of security

There were no trading suspension orders issued by the SEC in the past 12 months

**Item 4      Issuance History**

The Company issued 25,000,000 restricted Common shares to one individual prior to new management.

The Company issued 10,000,000 restricted Preferred C shares in lieu of employee compensation. (The Company is currently looking into this Issuance as this was done by prior management and Preferred Series C shares can only be purchased through the Company's Private Placement Memorandum)

The Company issued 165,000,000 restricted common shares to three employees for services rendered to the Company 11/2/14

The Company sold 420,000,000 restricted common shares to seven individuals 10/2/14

The Company sold 400,000,000 restricted common shares to an individual on 2/1/14.

The Company sold 2,000,000 restricted Preferred A shares to an individual on 2/1/14

The Company sold 16,000,000 restricted common shares on 7/2/13.

All shares issued by the Company were restricted and included the legend that the shares had not been registered under the Securities Act.

## Item 5

	June 30, 2015	March 31, 2015	December 31, 2014	December 31, 2013
<b>ASSETS</b>				
<b>Current Assets</b>				
Cash	5,397	21,420	5,207	8,053
Prepaid Expenses		12,500	50,000	-
Accounts Receivable	(3,900)			
Inventory	19,548	11,859	8,000	13,568
Due from Shareholder				
Matthew Nicoletti	100			
Michael Pannucci	100			
Robert Clark	100			
<b>Total Current Assets</b>	<b>21,345</b>	<b>45,779</b>	<b>63,207</b>	<b>21,621</b>
<b>Equipment, Net</b>				
Furniture and Equipment	2,760	10,500	10,750	11,750
zAccumulated Depreciation	(480)			
Deposits	-	-	33,700	8,700
Good Will		199,354	-	840,000
	2,280	199,354	33,700	848,700
<b>Other Assets</b>				
Patent Costs	3,565			
Prototype Costs	29,667			
zAccumulated Amortization	(1,187)			
<b>Total Other Assets</b>	<b>32,045</b>			
<b>Total Assets</b>	<b>\$ 55,670</b>	<b>\$ 255,633</b>	<b>\$ 107,657</b>	<b>882,071</b>
<b>LIABILITIES AND STOCKHOLDER'S EQUITY</b>				
<b>Current Liabilities</b>				
Due to related part	-0.02		8,000	
<b>Total Current Liabilities</b>	<b>(0.02)</b>	<b>-</b>	<b>8,000</b>	<b>-</b>
<b>Long Term Liabilities</b>				
Notes Payable - Related Parties		21,800	-	6,280,571
<b>Total Long Term Liabilities</b>	<b>-</b>	<b>21,800</b>	<b>-</b>	<b>6,280,571</b>
<b>Stockholder's Equity (Defecit)</b>				
10,000,000 Preferred C shares issued as employee compensation (value: \$100,000)		100,000	2,880	880
Capital Stock				
Common Stock ( 25,000,000 Common Stock)	1,237,054	1,237,054	1,222,054	222,395
Retained Earnings	(125,031)			
Additional Paid in Capital	1,989,793	1,934,427	1,910,927	2,228,352
Deficit	(3,046,146)	(3,037,648)	(3,036,204)	(7,850,127)
	55,670	233,833	99,657	(5,398,500)
<b>Total Liabilities and Stockholder's Equity</b>	<b>55,670</b>	<b>255,633</b>	<b>107,657</b>	<b>882,071</b>

Vencor International, Inc.  
 Statements of Operations  
 Quarter Ending June 30, 2015

	June 30, 2015	March 31, 2015	December 31, 2014	December 31, 2013
<b>Cash Flows From Operating Activities</b>				
Net Income (Loss)	\$ (8,498)	\$ (2,103)	\$ 4,814,582	\$ (148,492)
Adjustments to Reconcile Net Loss to Net Cash Used by Operating Activities				
Depreciation Expense		250	1,000.00	250
Goodwill Expense			840,000	
Forgiveness of Debt			(6,280,571)	
Prepaid Expenses			(50,000)	
Inventory	1,391	(3,859)	5,568	(13,568)
Deposits			(25,000)	
Stock Issued to Repay Debt			4,200	
Common Stock Issued for Services			165,000	
<b>Net Cash Used by Operation Activities</b>	<b>(7,107)</b>	<b>(5,712)</b>	<b>(525,221)</b>	<b>(161,810)</b>
<b>Cash Flow from Investing Activities</b>				
Increase Due to Related Party			8,000	
Purchase of FFE				(12,000)
<b>Net Cash Provided by Investing Activities</b>	<b>-</b>	<b>-</b>	<b>8,000</b>	<b>(12,000)</b>
<b>Cash Flows from Financing Activities</b>				
Proceeds from Issuance of Common Stock		15,000	469,697	
Proceeds from Issuance of Preferred Stock		100,000	33,333	
Notes Payable			-	(12,000)
Stockholder Contributions		23,500	12,004	91,747
Capital Investment	7,556			
<b>Net Cash Provided by Financing Activities</b>	<b>7,556</b>	<b>138,500</b>	<b>515,034</b>	<b>79,747</b>
<b>Net Change in Cash</b>	<b>448</b>	<b>16,213</b>	<b>(2,846)</b>	<b>(94,063)</b>
Cash in Beginning of Period	4,869	5,207	8,053	102,116
Opening Balance Equity	80			
PayPal - One time deposit	0			
<b>Cash at End of Period</b>	<b>\$ 5,397</b>	<b>\$ 21,420</b>	<b>\$ 5,207</b>	<b>\$ 8,053</b>
<b>Supplemental Cash Flow Information</b>				
Cash Paid During the Period for:				
Interest	\$ -	\$ -	\$ -	\$ -
Income Taxes	\$ -	\$ -	\$ -	\$ -

Vencor International, Inc.  
Statements of Operations  
Quarter Ending June 30, 2015

	June 30, 2015	March 31, 2015	December 31, 2014	December 31, 2013
Revenue, net	\$ 3,500	\$ 6,000	\$ 39,860	\$ 6,458
Cost of Goods Sold	1,550	3,500	10,464	3,875
Gross Income	1,950	2,500	29,396	2,583
Expenses				
Accounting and Legal Fees	2,085	2,000		500
Professional Fees	3,000		355,909	34,148
Officer's Compensation			185,000	
Insurance			990	
Depreciation			1,000	250
Computer and Internet			60	30
Moving Expense				1,485
Office Supplies	16	138	396	418
Postage	308		670	159
Professional Fees				2,000
Rent	1,598		31,200	14,800
Samples				357
State Taxes				43
Telephone		600	2,375	1,256
Travel	282	1,865	2,181	3,882
Utilities	382		496	
Website Design			2,000	
Miscellaneous	264		659	
Merchant Services Fee				
Meals and Entertainment	84			
R & D / Prototyping	2,169			
Advertising and Promotion	36			
Bank Service Charges	36			
Repairs and Maintenance				
Partial Public Expense				
Google Apps Monthly Fee	89			
Tradeshaw	100			
	10,448	4,603	582,277	59,328
Net loss before other income and expenses	(8,498)	(2,103)	(552,881)	(56,745)
Other Income and Expenses				
Forgiveness of bad debt			6,207,463	
Goodwill Expense			(840,000)	
Interest Expense			-	(91,747)
		-	5,367,463	(91,747)
Net Income (Loss)	(8,498)	(2,103)	4,814,582	(148,492)
Loss Per Common Share - Basic and Fully Diluted		(0.000)	0.01000	0.00010
Weighted Average Number of Shares Outstanding -Basic and Fully Diluted		1,247,053,690	643,589,512	222,394,690

Vencor International, Inc.  
Statements of Stockholder's (Deficit)  
Quarter Ending June 30, 2015

	Common Stock		Preferred Stock		Additional Paid		Total Stockholder's Deficit
	Shares	Amount	Shares	Amount	in Capital	Deficit	
Balance January 1, 2013	222,394,690	222,395	880,000	880	2,136,605	(7,701,635)	(5,341,755)
Contribution to Additional Paid in Capital					91,747		91,747
Net Loss						(148,492)	(148,492)
Balance December 1, 2013	222,394,690	222,395	880,000	880	2,228,352	(7,850,127)	(5,398,500)
Issuance fo Common Stock	14,659,000	14,659			388,371		403,030
Issuance fo Common Stock	400,000,000	400,000			(333,333)		66,667
Issuance fo Preferred Stock			2,000,000	2,000	31,333		33,333
Issuance fo Common Stock to Repay Loan	420,000,000	420,000			(415,800)		4,200
Issuance fo Common Stock fo Services	160,000,000	160,000					160,000
Issuance fo Common Stock fo Services	5,000,000	5,000					5,000
Contribution to Additional Paid in Capital					12,004		12,004
Net Income						4,814,582	4,814,582
Balance December 31, 2014	1,222,053,690	1,222,054	2,880,000	2,880	1,910,927	(3,035,545)	100,316
Contribution to Additional Paid in Capital					23,500		23,500
Issuance fo Common Stock	25,000,000	15,000					15,000
Issuance fo Preferred C Stock fo Services			10,000,000	100,000			100,000
Net Income						(2,103)	(2,103)
Balance March 31, 2015	1,247,053,690	1,237,054	12,880,000	102,880	1,934,427	(3,037,648)	236,713
Contribution to Additional Paid in Capital					25,671		
Capital Investment					29,695		
Capital Stock							
Issuance fo Common Stock							
Net Income						(8,498)	
		1,237,054			1,989,793	(3,046,146)	

## Item 6 Business Information

- A. PLAD, Inc. is a medical device development company that intends to design, patent, and market medical devices related to patient handling niche markets. Two devices have already been designed with the participation of leading firefighters, paramedics, and nurses involved with patient handling. Three patents are initially incorporated. The company projects upwards of \$2.4 million in sales in year three. The patent application on its first market entry has already been accomplished using a top patent law firm.
- B. In 1981 Blue Ridge, Inc., a publically traded company, was incorporated in the State of Utah. Blue Ridge, Inc. bred champion horses. In 1984, Vencor Corporation was incorporated as a private company to produce and market DiDeeSnug Diaper, an environmentally responsible cloth diaper that was both washable and reusable. On March 14, 1986, the Vencor Corporation was merged into Blue Ridge, Inc. Under the terms of the merger, the combined entity changed its name to Vencor International, Inc.
- C. The Company's primary SIC code is 5047
- D. The Company's fiscal year end is December 31.

- E. The mission of PLAD, Inc. is to create innovative patient lifting products that eliminate personnel injuries from patient handling. These products will be manufactured from the highest quality materials, will be lightweight, compact, and portable, and will be able to safely lift patients in a variety of situations. We strive to make the workplace environment for personnel involved with patient handling a safer place to be and a more comfortable experience for the patient.

**Item 7 Facilities**

The Company recently relocated its corporate office to Rockledge, FL.

**Item 8 A. Officers, Directors, and Control Persons**

Officers and Directors

CEO: Bobby Clark

President: Michael Pannucci

Sales Manager: Matthew Madeira

Chairman: Scott Forsythe

**B.** None of these persons have, in the last five years, been subject to any legal or disciplinary action by any legal authority, including the SEC.

**C.** Beneficial Shareholders

Persons owning more than five percent (5%) of the issuer's securities as of the date issued:

<b>James Gaspard</b>	100,000,000 restricted common shares
<b>Scott Forsythe:</b>	400,000,000 restricted common shares

**Item 9 Third Party Providers**

**Legal Counsel:**

**Accountant:** None

**Item 10 Management Discussion and Analysis**

In 1981 Blue Ridge, Inc., a publically traded company, was incorporated in the State of Utah. Blue Ridge, Inc. bred champion horses. In 1984, Vencor Corporation was incorporated as a private company to produce and market DiDeeSnug Diaper, an environmentally responsible cloth diaper that was both washable and reusable. On March 14, 1986, the Vencor Corporation was merged into Blue Ridge, Inc. Under the terms of the merger, the combined entity changed its name to Vencor International, Inc. From its start to October 1989, Vencor developed and test marketed the DiDeeSnug diaper. DiDeeSnug is made from 100% cotton, is form fitting and has elasticized leg openings. Its Velcro® closures at the waist allow users to adjust the diaper to the exact size of the baby's waist. Consequently, there was no use

and/or need for safety pins.

Although Vencor was established as a public company in 1986 it did not start selling DiDeeSnug at the national market level until early 1990. During this interim period Vencor spent considerable time and effort developing and test marketing the DiDeeSnug diaper in order to make sure it had properly developed this product.

In late 1991 and 1992, consumers lost interest, to some degree, in the environmental issues associated with disposable diapers. Meanwhile, given the nation's economic recession, retailers no longer wanted to invest in any new product inventory. For their part, consumers did not want to make the up-front investment in reusable diapers. All of this led Vencor to start investigating other product opportunities/ideas.

Drawing on its established expertise in infant diapers, Vencor decided in August 1992 to enter the adult incontinent market. Concurrent with the incontinent effort, mentioned above, Vencor also developed a line of novelty infant sleepwear products. The decision to develop an infant sleepwear line came during the fall of 1992, while Vencor was developing its adult incontinent products. Company management realized that the adult incontinent line would take time to fully develop and that an infant sleepwear line could be introduced more quickly to boost Vencor's cash flow. As such, Vencor began to develop and merchandise a line of sleepwear products.

In October of 1999, Vencor changed its name to Regal Apparel Group, Inc. On March 29, 2003, the Company changed its name back to Vencor International, Inc.

In Mid-2003, ACCUDX became part of VENCOR. ACCUDX was a development stage company offering at-home testing for HIV and Hepatitis C. These testing products could be purchased over the Internet. The Company also planned to sell them over the counter at both drug stores and grocery stores. These quick tests were in the process of being approved globally and orders were pledged in Pakistan, Thailand, Switzerland Italy and Armenia. The financing for this project was delayed so this division never went forward to full production and finally was transferred back to the original owner ACCUDX in May of 2005.

October 1, 2008 Vencor International, Inc entered into a purchase agreement with Leisureworks Group, LLC a Nevada LLC. Vencor entered into an "Asset Purchase Agreement" the purchase amount was \$1,500,000 included in the agreement was the company name Leisureworks Group, LLC and is administered as such. The purchase price was for brand label value of "Robeworks" and "Leisureworks" plus inventory and equipment. November 1, 2008 Leisureworks Group, LLC entered into an agreement with Victiore, LLC to sell the rights of the Robeworks brand label, its inventory and customer list for \$575,600. Victiore, LLC paid \$175,600 as a down payment and Leisureworks Group, LLC carried a \$400,000 note at 6% interest per annum. The monthly payment principal and interest is \$9,394.01 for 4 years.

From 2009 to 2013, VENCOR was engaged in the business of the sales of robes and Leisurewear through wholesale channels; designing, merchandising and production investment for re-entry into the market in activewear; and finalizing international website development.

In 2014 Vencor International was in the business of providing torrefied wood pellets to customers around the world. Torrefied wood pellets are made from timber field waste using a process called torrefaction. Torrefied wood pellets are a renewable energy source that can replace traditional coal.

On August 10, 2015 PLAD, Inc. purchased Controlling Interest in Vencor International, Inc. and merged PLAD, Inc., a Florida Corporation into the Company. PLAD's goal is to eliminate the possibility of back injuries from performing non-emergent lift assists that are performed daily by firefighters, E.M.S. personnel, Assisted Living personnel, Nursing Home personnel, and home health workers. We've created an industry first lifting device that is light weight and portable, battery powered, can be deployed in a matter of minutes by one or two people, and can lift a patient from the ground to a standing position, into a chair, into a wheelchair, or onto a stretcher with just a pull of a trigger.

PLAD, Inc. is a medical device development company that intends to design, patent, and market medical devices related to patient handling niche markets. Two devices have already been designed with the participation of leading firefighters, paramedics, and nurses involved with patient handling. Three patents are initially incorporated. The company projects upwards of \$2.4 million in sales in year three. The patent application on its first market entry has already been accomplished using a top patent law firm.

The market segments are clearly defined and all are subject to a high growth trend. One market has grown over seven percent from 2013-2014 and is expected to increase on the same trajectory. That is the firefighter/paramedic market. One of the founders of PLAD is currently a firefighter/paramedic and has provided in-the-field feedback to improve upon our product significantly during development phases. Another market segment addresses an area that has been untouched and seen little evolution in patient handling: hospitals, VA clinics, nursing homes, and assisted living facilities. Our new innovative design has been created to answer the needs of personnel in these fields.

This is a several hundred million dollar market and as current outdated equipment becomes obsolete, facilities will be looking for innovative replacements. The company becomes mature in year three. The company is potentially profitable in year one if projected sales are met.

PLAD, Inc. will initially market three distinct products.

- a) The Pro-Lift LX, a compact, lightweight, battery powered portable lift assist device.
- b) The Pro-Lift EX, a compact, lightweight, battery powered expandable portable lift assist device.
- c) The Pro-Lift BX, a compact, lightweight, battery powered bariatrics portable lift assist device.

The technology used in these products is the subject of three patents, one of which is in the application process.

These three product areas may be more generally defined as follows:

1. **Portable Lift Assist Devices--used for lifting patients off the ground**  
The Pro-Lift LX: Consisting of a lift that safely and comfortably lifts a patient weighing up to 500 lbs. off the ground.
2. **Portable Lift Assist Devices --used for lifting patients out of a bed.**  
The Pro-Lift EX: Consisting of a lift to lift patients out of a bed and maneuver them around a room, hallway, and bathroom.
3. **Portable Lift Assist Devices --used for lifting bariatric patients.**  
The The Pro-Lift BX: Consisting of a lift to lifting a patient weighing up to 750 lbs.

A detailed and technical description of the PLAD, Inc. initial product line follows:

### **Pro-Lift LX**

Applications include private ambulance companies, fire departments, E.M.S. and home users. Current solutions are physically lifting the patient by two or more personnel or inflatable air mattresses that don't allow you to put a wheelchair or stretcher under the patient.

**PLAD Technology:** Our Pro-Lift LX is our most portable lift assist device primarily used by firefighters, E.M.S., private Ambulance companies, and other first responder personnel. The Pro-Lift LX can be carried by one person and deployed in as little as 1-2 minutes. It has the lifting capacity to safely lift a person weighing up to 500lbs off the ground and comfortably place them in a chair, a wheelchair, or on to a stretcher. The Pro-Lift LX is the industry's first such product to the market and sets the standard in safe patient handling for first responders.

**Further Advantages:**

- C. Eliminates the potential for lifting injuries
- D. Eliminates the need for team lifts
- E. Eliminates the need to call for extra resources
- F. Greatly cuts down on time to lift an individual
- G. Provides a comfortable lift for patient, reducing skin tears and breaking bones
- H. Operating cost savings

**Summary of advantages over currently available products:**

1. Light weight and compact for ease of portability.
2. 1-2 minute deployment, cutting down on call and lift time.
3. Single person operation to lift a patient weighing up to 500 lbs.
4. Accommodates standard wheel chair and stretcher to place patient in or on.
5. Significant savings in operations cost.

**Pro-Lift EX**

Applications include hospitals, VA facilities, nursing homes, and assisted living facilities. Current solutions are either expensive ceiling lifts that have to be installed per room or out dated crane style lifts that lift from the side of the bed.

**PLAD Technology:** Our Pro-Lift EX will be a facility based portable lift assist device. The Pro-Lift EX can be carried by one person and deployed in as little as 1-2 minutes. It has the lifting capacity to safely lift a person weighing up to 500lbs off the ground, from a bed, or a seated position and comfortably place them in a chair, a wheelchair, or on to a stretcher or bed. The Pro-Lift EX is the industry's first such product to the market that is expandable horizontally so that it can wheel around the bed offering stability of a ceiling mount lift, but greater portability and flexibility that a crane style lift.

**Further Advantages:**

- Simple design, allowing easy deployment and takes up minimal storage space when stowed.

- Adjustability allowing the product to fit around all standard medical beds, yet able to fit through standard doorways.
- Lightweight and user friendly.
- Can fit in tight spaces to safely lift a patient in a variety of scenarios.
- Utilizes most harness systems available on the market.

## **Pro-Lift BX**

Applications include Fire departments, private ambulance companies, E.M.S., hospitals, VA facilities, nursing homes, and assisted living facilities. Current solutions are either none existent or custom applications.

**PLAD Technology:** Our Pro-Lift BX will be a bariatrics portable lift assist device capable of lifting patients weighing up to 750 lbs. The Pro-Lift BX will have a larger footprint and weigh more than the LX and EX, but will still maintain portability. It will have the lifting capacity to safely lift a person weighing up to 750 lbs off the ground, from a bed, or a seated position and comfortably place them in a chair, a wheelchair, or on to a stretcher or bed. The Pro-Lift BX will be the industry's first such product to the bariatrics market, addressing the demand for a product to lift larger patients.

**Advantages over currently available products:** No Products Currently Available.

## ***Competitive Comparison***

The leading product currently available in the patient handling market is the Hoyer lift, which is generally found in hospitals and is not designed to be portable. Other product entries are from HoverJack and Binder Lift. These two products are used in the E.M.S. field. Both products require personnel to still physical handle the patient in conjunction with their device.

Bobby Clark, a founder of PLAD and one of the developers of PLAD's patented technologies is aware of both its strengths and shortcomings of competing products. The Pro-Lift LX is a much improved product in a rapidly growing market application. Many of the product advantages were highlighted in the previous section of this plan. To summarize the key advantages:

- I. Eliminates the potential for lifting injuries
- J. Eliminates the need for team lifts
- K. Eliminates the need to call for extra resources
- L. Greatly cuts down on time to lift an individual
- M. Provides a comfortable lift for patience, reducing skin tears and breaking bones

The Pro-Lift LX represents an entirely new application with no current competition. Its use can potentially range from lifting a patient off the floor and lifting them into a standing position, place them in a wheelchair, or place them onto a stretcher. This solves the well documented and acknowledged problem of the lack of devices needed for

non-emergent lift assists. The Pro-Lift LX also allows an improved and more efficient means of safely lifting a patient off the ground.

### ***Future Products***

Plans for future development by PLAD include additional ideas and technologies to be created by Bobby Clark CEO as well as the rest of the PLAD management team for PLAD and an outside engineering firm yet to be determined. In addition PLAD may seek to acquire technologies developed by others once it attains sufficient capitalization to do so. It is the objective of PLAD to both innovate and market its products. Once an industry reputation has been achieved and marketing channels opened expansion into other medical device areas becomes potentially rewarding.

### ***Industry Analysis***

The E.M.S. and health care industry in the United States has seen a rising trend in patient handling related injuries in the workplace. Safe patient handling programs are on the rise and being put in place to combat the costs associated with workers compensation claims from personnel injuries. PLAD is ideally positioned to capitalize on this trend for the following reasons:

1. Low cost patient lift assist device
2. Personnel never needs to physically lift the patient
3. Quick deployment
4. Patient comfort while being lifted
5. Positioned ideally for E.M.S. and healthcare personnel
6. Operation costs savings and quick ROI

### ***Main Competitors***

Competitors differ regarding PLADs target markets. With the market of E.M.S., there are currently no direct competitors, but competitors that do offer patient lifting devices. These devices consist of inflatable air mattresses, patient vests with multiple handles, and patient belts with multiple handles.

Within the healthcare industry, the most important competitor will be Hoyer, which offers a crane style lift. Its strengths are its current market position and longevity in the market. Its weakness is its reputation of not being user friendly and not being particularly innovative. This makes it vulnerable to a new, improved entry into the market.

### ***Distribution Patterns***

Distribution patterns in the E.M.S. and health care industry are such that the large buying groups dictate what products are used for certain protocols throughout their sphere of influence. Thus, our products could be mandated or forced out for thousands of fire departments or hospital groups.

### ***Management Team***

Bobby Clark (38)

BS, Management Information Systems, University of Central Florida 2003

Bobby Clark is the CEO and Cofounder of PLAD, Inc. Mr. Clark drive's the company's vision, strategy, and growth and oversees product design and manufacturing. PLAD has developed the industry's first lightweight, compact, battery powered portable lift assist device that allows for safe patient handling in hospitals, nursing homes, assisted living facilities, VA Centers, and in the E.M.S. and firefighter fields.

Mr. Clark has held several leadership positions prior to cofounding and becoming CEO of PLAD. He earned a Bachelor's Degree in Business Administration and Management Information Systems and has over 12 years of experience in the product design and technology fields.

Prior to PLAD, Mr. Clark worked with, at the time, a new emerging wireless company, where he assisted in developing cutting edge wireless and wired products. That company later went on to be acquired by a Fortune 100 company.

Mr. Clark is involved in several safe patient handling programs aimed at reducing personnel injuries in fields where patient handling is involved. His goal, along with PLAD's, is to provide innovative patient lifting products that eliminate personnel injuries, which in turn will save companies and municipalities millions of dollars from injury and nuisance claims.

Mike Pannucci (35)

BS, Interpersonal Communications, University of Central Florida, 2002

Mike Pannucci is the President and Cofounder of PLAD, Inc. Mr. Pannucci drive's the company's vision on product design and building lasting customer relationships.

Mr. Pannucci has spent the last 5 years working as a firefighter/paramedic. In his career has a firefighter/paramedic, Mr. Pannucci identified a void in the market for a portable lift assist device, thus creating the vision to design such a device. His experience in the E.M.S. field has provided PLAD with invaluable knowledge, statistics, feedback, and access to E.M.S. leaders and decision makers. He has been able to bring feedback from the field and parlay that feedback into design features of our Pro-Lift LX.

Scott Forsythe, Chairman:

Mr. Forsythe is the founder and owner of a successful computer supply wholesale business that he established in 1997 and continues to serve as president and director of the company. Prior to starting his current business, which has generated over \$14 Million in revenue per year, Mr. Forsythe was a top sales rep at Horizon Data Corp. (1992-1997) and Burroughs Corp. (1976-1988) in Florida. Mr. Forsythe has a Bachelor of Science degree in Marketing from Florida State University. PLAD's Board of Directors believes that Mr. Forsythe's management experience, keen business insight and the vendor and business relationships that he developed over the years will be invaluable to the Company's future growth.

### ***Inherited Public Company Costs***

The Company has spent a substantial amount of money cleaning the books and records of the public company as well as getting the Company back to good standing with the Transfer Agent, OTC Markets and various other service providers. The Company's management team is currently looking into canceling share issuances done by prior management before their resignation. These issuances were issued to prior management and affiliates of prior management.


### ***Private Placement Memorandum***

PLAD, Inc. will be offering a Private Placement Memorandum to Accredited Investors to raise funds for the Company. Management feels this is the best way to raise funds so its shareholders will not be diluted. The Company has no current plans to raise funds using Free Trading Shares. The Company will use funds raised to develop additional products, acquire additional subsidiaries and help grow the Company to increase value.

### ***Mission***

The mission of PLAD, Inc. is to create innovative patient lifting products that eliminate personnel injuries from patient handling. These products will be manufactured from the highest quality materials, will be lightweight, compact, and portable, and will be able to safely lift patients in a variety of situations. We strive to make the workplace environment for personnel involved with patient handling a safer place to be and a more comfortable experience for the patient.

### **Chart: Highlights**



## **Keys to Success**

The keys to success for PLAD, Inc. are as follows:

1. Initial capitalization obtained.
2. All patent applications filed.
3. The ability to generate early revenue from private ambulance companies and volunteer fire departments.
4. Recruiting top-notch Sales Representatives.
5. Successful 510k approval from FDA to market Pro-Lift EX and Pro-Lift BX models to hospitals.
6. Successful implementation of sales and marketing plan to U.S. managed care market to obtain a minimum 10% market share in the third full year to generate \$2.4 million in revenue.
7. Increased product development and continued market share gains to continue upward revenue growth.

## **Company Summary**

PLAD, Inc. will develop and market portable lift assist devices through multiple distribution channels domestically. The company is currently selling our Pro-Lift LX model and developing its patent-applied technologies to its second product and approval stage. It is also seeking to establish its corporate identity in the E.M.S and medical products field. Growth strategy calls for the following objectives:

1. Complete the patent process.
2. Establish corporate identity, brand names, and trademarks.
3. Establish an advisory board.
4. Build staff, infrastructure, and retain consultants for trial and compliance issues.
5. Prepare for FDA 510k.
6. Continue R & D and product development.
7. Explore options for 2nd round financing (venture capital, corporate alliance, licensing, and public offering) to maximize value to shareholders.

## **Item 11 Issuer Certification**

I, Bobby Clark, certify that:

1. I have reviewed this Quarterly Disclosure Statement of Vencor International, Inc.;  
and
2. Based on my knowledge, this Disclosure Statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Disclosure Statement;  
and

3. Based on my knowledge, the Financial Statements and other financial information included or incorporated by reference in this Disclosure Statement, fairly present in all material respects, the financial condition, results of operations and cash flows of Vencor International, Inc. as of and for the periods presented in this Disclosure Statement.

October 12, 2015

A handwritten signature in cursive script that reads "Bobby Clark".

---

Bobby Clark  
Chief Executive Officer